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While the phenotype of Parkinson disease (PD) is heterogeneous, treatment approaches 
are mostly uniform. Personalized medicine aims to treat diseases with targeted therapies 
based on cumulative variables, including genotype. We believe that sufficient evidence 
has accumulated to warrant the initiation of personalized medicine in PD based on 
subjects genotype and provide examples for our reasoning from observations of GBA 
and LRRK2 mutations carriers. While PD patients who carry the G2019S mutation in 
the LRRK2 gene seem to develop relatively mild disease with more frequent postural 
instability gait disturbance phenotype, carriers of mutations in the GBA gene tend to 
have an early onset, rapidly deteriorating disease, with more pronounced cognitive and 
autonomic impairments. These characteristics have significant implications for treatment 
and outcome and should be addressed from an early stage in the attempt to improve 
the patient’s quality of life.
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iNtrODUctiON
Parkinson disease (PD) is a complex neurodegenerative disorder affecting older adults. The etiology 
of PD is heterogeneous, genetic, and multi-factorial, resulting in a highly variable clinical course, 
spanning from a slowly progressive, benign course to a rapidly progressive, disabling disease (1, 2).
Parkinson disease is a highly variable disease; it can start early in the 3rd or 4th decade of life, or 
as late as the 10th decade, the predominant symptom can be tremor, or the disease phenotype might 
be non-tremulous with gait, postural impairments, or rigidity as the main features. PD can involve 
late or early cognitive and behavioral changes, early or late autonomic disturbances, and various 
manifestation of pain or sleep disturbances (3–5). However, in spite of this large diversity in clinical 
features, the therapeutic approach, as reflected in therapeutic guidelines, is uniform and symptom 
oriented, with the exception of age and cognitive state as factors influencing clinical decisions (6, 7). 
Recent understanding of the significant contribution of multiple gene loci to the risk of developing 
PD, as well as to the disease phenotypic clinical course, raise the possibility of tailoring an individual-
ized therapeutic strategy based on the patients’ genetic and personal background (8).
Ashkenazi Jews (AJ) constitute a unique population to start implementing such genetic-based 
personalized approach since more than one-third of AJ-PD patients have a known mutation in 
either the GBA (eight mutations) or the LRRK2 (G2019S) genes (9, 10). Herein, we will highlight 
some clinical features of GBA or LRRK2-associated PD among the AJ population and propose a new 
tABLe 1| Differences in symptomatology based on genetic status as 
compared to iPD.
LRRK2 GBA
Age of onset Similar to iPD (30) Earlier than iPD (27)
Hyposmia Better than iPD (15) Significant (47, 53)
Cognitive decline Better cognitive performance 
(11, 12)
Significant (22, 23, 54)
Depression Reports of both higher and 
lower frequencies (17, 20)
More severe (55)
RBD Less than iPD (13,14) More severe (53, 55)
Motor phenotype PIGD (16, 29) More postural instability (31)
Specific targeted 
pharmacological 
treatment
Ursedeoxycholic acid (56) Ambroxol (57)
Autonomic Less than iPD (58) More severe involvement (23)
Dyskinesia Same as iPD (39) More severe compared to 
iPD (40)
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vision for personalized medicine based on genetic background. 
The immediate consequence of such genetic-based personalized 
approach is the need to genetically test for GBA and LRRK2 muta-
tions all recently diagnosed AJ-PD patients, patients entering 
clinical trials and those referred to deep brain stimulation (DBS). 
It is important to stress that the clinical genetic correlation we 
report here is based mostly on retrospective data and the pro-
posed clinical approach has never been examined in prospective 
long-term care. We hope this paper will lead a scientific discus-
sion and encourage prospective studies and will be the first step in 
the development of a personalized approach in the development 
of therapeutic strategies for patients with PD.
LRRK2-G2019s PD
LRRK2-G2019S PD has been reported to manifest with a mild 
phenotype with less cognitive impairments (11, 12), higher 
frequencies of sleep onset insomnia, and equal frequencies of 
daytime sleepiness but less REM sleep behavior disorders (RBD) 
compared to idiopathic PD (iPD) (13, 14). LRRK2-G2019S PD 
patients seem to express better olfactory function compared to 
iPD patients (15) and appear to present more frequently with the 
postural instability gait difficulty (PIGD) sub-type (16), although 
in another publication tremor was identified as a distinguished 
feature of LRRK2-PD (17). Some discrepancies appear in the 
literature relating to the presence of higher prevalence of psy-
chiatric symptoms in LRRK2-G2019S PD patients (18, 19) while 
other studies could not detect such a trend (11). Both higher and 
lower rates of depression in LRRK2-G2019S PD patients have 
been reported compared to iPD (17, 20).
GBA-PD
Studies reported that heterozygous, homozygous, and 
compound-heterozygote GBA-PD patients present with more 
severe cognitive decline compared to iPD (21–23). The asso-
ciation between mutations in the GBA gene and early cognitive 
decline has recently received much support by observations that 
GBA carriers frequently develop Lewy Body Dementia (LBD), 
a syndrome that is tightly associated with PD and is one of the 
classical synucleopathies, defined by the development of clini-
cally significant cognitive decline prior to, or at about the same 
time as, the appearance of parkinsonism (24). In addition, higher 
incidence of RBD, a known marker for cognitive decline in PD, 
was reported in GBA-PD patients (25) as well as more frequent 
psychiatric symptoms than in iPD (26). Carriers of severe GBA 
mutations were found to have an earlier onset PD symptoms (27) 
and more autonomic disturbances at PD diagnosis and as the 
disease progressed, reflecting earlier and more sever autonomic 
degeneration (27) (Table 1).
How PD Differs in Patients with  
LRRK2 or GBA Mutations?
Early in the Clinical Course
Gait
Early postural instability and gait disturbances in PD is known 
to be associated with earlier falls, more freezing of gait (FOG) 
and more frequent cognitive decline (28). A large proportion of 
LRRK2-G2019S-PD patients were found to present with PIGD 
phenotype that is associated with higher risk of falls (29, 30). 
Similarly, GBA-PD mutation carriers demonstrated increased 
gait impairments and FOG, which has been associated with 
disturbed executive functions (31). Such decline in functional 
performance is an indirect marker of decreased motor-cognitive 
reserve, which should be taken into account while developing 
treatment strategies.
Parkinson disease patients, with either LRRK2-G2019S 
mutation or any mutation in the GBA gene, should be informed 
about their higher risk for earlier falls or FOG, and treatment 
should be offered to try and delay or prevent these serious motor 
complications. Such recommendations will include using extra 
caution when offering drugs that increase fall risk, such as anti-
depressive drugs, benzodiazepines, hypnotics, anti-cholinergics 
and possibly dopamine agonists (DA) because of their effect on 
alertness (32, 33). In conjunction, physical or cognitive therapy 
should be recommended and encouraged as early as possible and 
reinforced in every visit. Prevention of falls and FOGs should 
be a  priority in order to avoid the need for treatment of their 
destructive consequences.
Early Cognition–Mood Changes
The tendency for earlier, faster, and more clinically meaningful 
cognitive decline in GBA-PD should be a major consideration 
in treatment strategy. In view of the negative impact of all anti-
parkinsonian drugs on cognition, alertness, sleep, and the risk 
of psychosis (34), drug choices or drug combinations should 
be prescribed more cautiously than when treating iPD patients. 
In addition, cognitive state, sleep quality, mood (depression and 
anxiety), hallucinations, or delusions should be assessed in every 
visit of a GBA-PD patient, in an effort to establish early detection 
and to prevent sever psychosis, a leading cause for hospitaliza-
tion and institutionalization (35). Intensive exercise programs 
and multi-domain cognitive enhancing interventions should be 
recommended early to enhance capacity and reserve, and the 
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above knowledge should be used to increase adherence to both 
short-term and long-term behavioral modifications.
Such variability in disease course and in the risk of developing 
significant complications, as well as drug-induced side effects 
in GBA-PD, must be taken into consideration when including 
patients into any clinical trial, but especially in studies testing 
disease modifying drugs.
Increased Risk of Experiencing Autonomic 
Disturbances
The higher rates of autonomic symptoms presented by GBA-PD 
patients (23) has major importance in treatment strategies since 
all anti-parkinsonian drugs can worsen or cause orthostatic 
hypotension while some can trigger urinary retention, delayed 
gastric emptying time, constipation, erectile dysfunction, delayed 
ejaculation, and lymphatic edema (36). The increased risk of early 
occurrence of clinically significant autonomic disturbances or 
treatment-induced autonomic complications should influence 
the therapeutic approach as well. Careful monitoring for early 
signs of autonomic dysfunctions in GBA-PD patients should be a 
recommended practice. Furthermore, the increased vulnerability 
of the autonomic nervous system should be taken into account 
when such patients are considered for participating in any drug 
or interventional clinical trials.
Later Disease stage Features
Dyskinesia
One of the most significant motor complication of dopaminergic 
treatment and especially levodopa is dyskinesia (37). Involuntary 
movements are frequently the biggest hurdle for effective dopa-
minergic treatment and the strategy to delay levodopa and use less 
effective substitutes, such as DA, was initiated specifically to delay 
these complications (38). LRRK2-PD patients were found to have 
equal frequencies of levodopa-induced dyskinesia compared to 
iPD (39). By contrast, it has been reported that GBA-PD patients 
are more sensitive to levodopa, developing dyskinesia earlier in 
the course of the disease (40). Combined with the earlier age of 
disease onset in GBA-PD (27), which is known to be associated 
with earlier and more aggressive Dopa-induced dyskinesia (41). 
GBA-PD patients should be considered from disease diagnosis to 
have increased risk for early disabling dyskinesia, lower dosages 
of levodopa and possibly, delaying levodopa should be common 
practice, even more than in the general PD population, in this 
group of GBA-PD patients.
should Mutation status influence 
referrals to Deep Brain stimulation?
The role of genotype in the outcome of DBS has not been well 
studied but it is possible that the risk to develop cognitive 
decline or gait disturbances, the two most common serious and 
long-term complications of DBS (42, 43) could be influenced by 
PD-associated mutations. Angeli et al. identified earlier cognitive 
decline in GBA-PD patients compared with controls (44), AJ 
LRRK2-PD patients had a similar outcome as iPD patients after 
subthalamic nucleus (STN) DBS (45), while a study in North 
African Arabs identified better outcome for LRRK2-PD patients 
after STN-DBS compared to iPD patients (46). Based on current 
knowledge, it could be speculated that more frequent behavioral 
and cognitive changes as well as earlier gait disturbances could be 
observed in PD patients, carriers of mutation in either the GBA 
or LRRK2 genes after DBS.
To the best of our knowledge, the effect of DBS on gait was 
not explored in the context of patients’ genetic status. Because 
of its cardinal clinical consequences, it is important to explore 
retrospective cohorts and retrieve information about the short- 
and long-term clinical outcomes of DBS to the globus pallidus 
interna and STN in patients with iPD as well as those with known 
mutations. Until such data are available, referring PD patients 
with mutations in the GBA or the LRRK2 genes to DBS should be 
done after special consideration and after sharing the potential 
risks with the patients and their families.
Parkinsonism as the Manifesting 
symptom of GD
Recent investigation into the association of Gaucher disease (GD) 
and PD has indicated that parkinsonism could be the first neuro-
logical symptom of GD (47). In addition, our group has recently 
assessed 1100 AJ-PD patients and found 12 subjects who were 
either homozygous or compound-heterozygous for mutations in 
the GBA gene, half of which were not aware of any GD symptoms 
(ahead of print). This has important implications regarding the 
potential for reduced bone density and increased fractures fol-
lowing falls, which is a further reason for genetic screening of the 
AJ population.
therapeutic Approach based  
on Genetic testing
Throughout the course of PD, many pharmacological options 
as well as non-pharmacological interventions are available for 
the treatment of disease symptoms. Decisions should be made 
regarding the first anti-parkinsonian drug to prescribe, whether 
to add DA or levodopa or rather start treatment with levodopa 
right away, how to treat depression, anxiety, and sleep disturbances 
and how to monitor autonomic dysfunctions. Later on, questions 
regarding the combination of drugs, the use of anti-cholinergic 
drugs, or cholinesterase inhibitors for treating cognitive decline 
or sleep impairments and RBD, and the use of atypical dopamine-
blocking agents, such as quetiapine or clozapine, should be 
addressed. In addition, the intensity and quality of physiotherapy, 
cognitive enhancement therapies, and falls prevention strategies 
are all available but, currently, not uniformly recommended and 
implemented. Lastly, a recent epidemiological study exploring 
environmental and behavioral habits, such as caffeine consump-
tion, found a possible risk-reducing interaction between caffeine 
consumption and LRRK2-PD (48). Yet, patients’ engagement in 
life-style modification strategies is highly variable, highly associ-
ated with the level of knowledge and commitment of patients 
and care-givers to the recommended non-pharmacological 
interventions.
We believe that the present knowledge about the different 
course of PD among AJ and non-Jewish patients based on GBA 
and LRRK2 mutations’ status and the extremely high frequency 
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of mutation carriers in the AJ-PD patients (35%) justifies early 
genetic screening and tailoring treatment approach based on 
patients’ genotypes. However, the reduced penetrance rates for 
these mutations (49, 50) suggest that other modifier genes may 
be responsible for both increased and reduced risk of developing 
PD in this unique population (51, 52) as well as other aspects of 
the disease and demand further elucidation. We further recom-
mend that the genotype needs to be considered when recruiting 
patients into clinical trials especially when examining the efficacy 
of novel drugs. Such approach could foster the recruitment of a 
smaller sample size in fewer centers. Moreover, exploring efficacy 
of a drug with specific biological target, such as on lysosomal 
activity should likely be first tested in patients with mutations in 
the GBA gene.
In the present paper, we lumped together our discussion on 
GBA mutation carriers although we believe that specific mutations 
may influence disease course and also the effect of medications. 
Currently, there is only limited information to support splitting 
the recommendations according to individual mutations, or as a 
group of “mild” or “severe” mutations. However, future studies 
will likely lead to refinement of this approach also within GBA-PD.
In conclusion, we believe that the available evidence in regard 
to the specific course of GBA or LRRK2 mutations’ associated PD 
is sufficient to recommend genotyping new PD patient (especially 
those with AJ background). Such genotyping should influence 
the therapeutic approach throughout the course of the disease 
and should also be considered when recruiting patients into 
clinical trials.
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